| First Author | Behar V | Year | 2018 |
| Journal | J Invest Dermatol | Volume | 138 |
| Issue | 12 | Pages | 2635-2643 |
| PubMed ID | 29908149 | Mgi Jnum | J:270528 |
| Mgi Id | MGI:6276455 | Doi | 10.1016/j.jid.2018.05.028 |
| Citation | Behar V, et al. (2018) A Hexokinase 2 Modulator for Field-Directed Treatment of Experimental Actinic Keratoses. J Invest Dermatol 138(12):2635-2643 |
| abstractText | Overexpression of hexokinase 2, and its binding to VDAC1 on the outer mitochondrial membrane of cancer cells, is key to their metabolic reprogramming to aerobic glycolysis, which enables them to proliferate. We describe Comp-1, an allosteric small molecule that selectively detaches hexokinase 2 from the mitochondria. Detachment of hexokinase 2 reduces glycolysis and triggers apoptosis in cancer cells, without affecting hexokinase 1-expressing normal cells. The anti-cancer activity of Comp-1 was demonstrated in the UVB-damaged skin model in SKH-1 mice. Topical treatment with Comp-1 led to 70% reduction in lesion number and area. This in vivo efficacy was obtained without local skin reactions or other safety findings. Mechanism-related pharmacodynamic markers, including hexokinase 2 and cleaved caspase 3 levels, are affected by Comp-1 treatment in vivo. Good Laboratory Practice toxicology studies in minipigs for 28 days and 13 weeks established no systemic toxicities and minimal dermal reaction for once-daily application of up to 20% and 15% ointment strengths, respectively. Thus, Comp-1 may address a significant unmet medical need for a non-irritating efficacious topical actinic keratosis treatment. |
